PEPTIDE TOLEROGENIC COMPOUND Russian patent published in 2022 - IPC A61K35/26 C07K14/47 C07K14/52 

FIELD: biotechnology.

SUBSTANCE: group of inventions relates to biotechnology and discloses an anti-inflammatory preparation based on mammalian spleen peptides, wherein the preparation is presented in the form of a dermal water-alcohol lotion of systemic anti-inflammatory action, containing a fraction of purified peptides of spleen of mammals with molecular weight of not more than 12 kDa in amount of 1÷5 wt. % to the total weight of the composition, 96 % ethanol in amount of 40 wt. %, sodium chloride in amount of 0–0.5 wt. %, zinc chloride in amount of 0–0.05 wt. %, calcium sulphate in amount of 0–0.2 wt. %, water is the rest, at pH 7.4 ± 0.2. Group of inventions also relates to a method of suppressing the inflammatory response and to the use of an anti-inflammatory preparation.

EFFECT: achieving anti-inflammatory therapeutic effect with underlying permanent forced overexpression of the most powerful pro-inflammatory cytokine - tumour necrosis factor (TNF-alpha - TNFα), that is, the preparation according to the invention provides not only an anti-inflammatory effect, but also exhibits tolerogenic action - initiates specific tolerance of T-regulatory cells to body own antigens, which causes its effectiveness in therapy of autoimmune inflammatory diseases; more effective stimulation of immature (naive) monocytes to Treg production, compared to cytokines GM-CSF + M-CSF, which are used in the classical Treg induction technique and can be present in peptide fractions from the spleen with molecular weight of more than 12 kDa, specifically about 30 kDa for GM-CSF and about 60 kDa for M-CSF, but are absent in the disclosed preparation based on the spleen peptide fraction with molecular weight of not more than 12 kDa; achieving systemic anti-inflammatory therapeutic action when using the preparation in the form of a water-alcohol lotion when applied to the skin, which causes a decrease in the concentration of pro-inflammatory cytokines TNFa, IL-1b and IL-2 in the blood; prevention of development of psoriatic and rheumatoid arthritis with efficiency of about 70 % due to systemic tolerogenic anti-inflammatory therapeutic action; achieving a tolerogenic anti-inflammatory therapeutic effect in a form suitable for out-of-hospital use; achieving systemic tolerogenic anti-inflammatory therapeutic action without undesirable side effects - allergic reactions and suppression of adaptive immunity.

14 cl, 2 tbl, 8 ex, 10 dwg